Ki-67 index in metastatic prostate cancer.
OBJECTIVE
Prostate cancer in bone is generally thought to progress more rapidly than in its primary site, a supposition that is supported by studies of prostate-specific antigen velocity. However, descriptions of proliferative rates in metastases have relied on inferred data from in vitro studies of cell lines derived from metastases. The aim of this study was to determine directly the proliferative rate within bone metastases arising from prostate cancer.


METHODS
10 bone biopsies containing metastatic deposits of untreated prostatic cancer were obtained. These were immunohistochemically stained for the Ki-67 protein with the monoclonal antibody MIB-1, using the streptavidin-biotin complex technique. Benign prostatic tissue was used as the control. Using an image analyser, the Ki-67 index (% of cells staining positively) in each specimen was determined.


RESULTS
In the 10 specimens the Ki-67 index ranged from 0.15 to 7.82%. Wide overlap was seen between groups of differing tumour differentiation.


CONCLUSIONS
The proliferative rate as determined by the Ki-67 index in bone metastases of prostate cancer is similar to that reported in primary tumours. There does not appear to be a relationship between tumour grade and proliferative index in these specimens.
Bryden
A A
AA
Department of Urology, Hope and Christie Hospitals, Manchester, UK. gbryden@hotmail.com
Freemont
A J
AJ
Clarke
N W
NW
George
N J
NJ
D000230:Adenocarcinoma / Q000378:metabolism / Q000556:secondary*; D000911:Antibodies, Monoclonal; D001859:Bone Neoplasms / Q000378:metabolism / Q000556:secondary*; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000378:metabolism*; D008297:Male; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000473:pathology*
D000911:Antibodies, Monoclonal; D019394:Ki-67 Antigen; D017430:Prostate-Specific Antigen